Lilly eyes more cancer deals, but wary of CAR-T, gene therapy
January 11, 2019 at 14:41 PM EST
Eli Lilly and Co remains in the hunt for cancer drugs even after announcing an $8 billion purchase of Loxo Oncology this week, but it plans to remain on the sidelines when it comes to two of the hottest areas of drug development.